Ms. Fang, a resident of Suzhou, is 48 years old. She had a harmonious family, good health and a happy life.
One day three years ago, Ms. Fang began to have a mild dry cough, which was only regarded as a cold and did not pay attention to it. However, the dry cough was repeated without sputum, and it did not heal for a long time. After an indirect laryngoscopy, it was found that the throat was inflamed and swollen. Ms. Fang and her family were not at ease, so she had a chest CT examination in the Radiology Department of the Second Affiliated Hospital of Soochow University. Uniform, with a lower density core in the center of the nodule, air bronchus sign +, vacuole sign -; tumor-lung junction: spinous process sign +, reverse concave sign +".
Chest CT showed pulmonary nodules, which may be manifestations of early cancer or benign disease. To further confirm whether the nodule is benign or malignant, the doctor recommended follow-up. After three years of four follow-up visits, the nodule size did not change significantly. Although there has been no malignant change in the past three years, the nodule still exists as a "time bomb". Ms. Fang and her family are always in a state of anxiety, so she asked the doctor if there is any better identification method.
Fortunately, the Second Affiliated Hospital of Soochow University and Jiangsu Weizhen Co., Ltd. jointly established the "Pulmonary Nodule Precision Diagnosis and Treatment Clinic" last year, which can assist CT in identifying lungs through Microdiag's exclusive "exosomal miRNAs and ctDNA joint inspection" technology. Micro nodules. The benign and malignant nodules can be better judged only by collecting blood without needle biopsy.
Ms. Fang and her family gladly accepted the doctor's advice, and then Ms. Fang's blood samples were sent to the Suzhou Premed Medical Laboratory under Microdiag Group for follow-up testing. Just three days later, the genetic test report of "exosomal miRNAs and CtDNA joint inspection" showed that the patient's exosomal micro RNA index value was 7.52, which was positive; the G12D mutation of KRAS in the ctDNA gene was also positive, which was interpreted as high. malignant risk. Based on the reported results and CT images, the doctor decided to perform surgery.
After Ms. Fang's operation, the tissue specimen was further confirmed to be microinvasive adenocarcinoma of the lung by pathology, and follow-up treatment was started in time. The prospect is very optimistic. Because lung cancer is usually found in the middle and late stages, the five-year survival rate is only 16.1%. If it can be detected early and treated in time, the long-term survival rate will be as high as 90%.
Ms. Fang and her family are very grateful to Jiangsu Microdiag Company after going through this near-miss experience. Thanks to Microdiag's exclusive "exosomal miRNAs and ctDNA joint inspection" technology for solving her long-term troubles!
The continuous innovation of science and technology will surely benefit more families of patients and bring more benefits to the society. Hope Ms. Fang will continue to maintain a healthy body and enjoy a happy life!